396
Participants
Start Date
March 31, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
December 31, 2016
Ruxolitinib
"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
Regorafenib
Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
Placebo
5 mg matching placebo tablets to be administered by mouth
Chandler
Gilbert
Mesa
Scottsdale
Los Angeles
Pasadena
Santa Barbara
Aurora
Colorado Springs
Denver
Altamonte Springs
Miami
Ocala
Orlando
Tampa
Niles
Lafayette
Ames
New Orleans
Baltimore
Jefferson City
St Louis
Lincoln
Omaha
Henderson
Las Vegas
Albany
Binghamton
Hudson
Johnson City
New York
The Bronx
Canton
Cincinnati
Portland
Charleston
Easley
Greenville
Greer
Sumter
Chattanooga
Nashville
Arlington
El Paso
Fort Worth
Houston
Paris
Plano
Tyler
American Fork
Bountiful
Murray
Provo
Salt Lake City
West Jordan
Roanoke
Vancouver
Bentleigh East
Herston
Kurralta Park
New Lambton Heights
Randwick
Avignon
Besançon
Le Mans
Lille
Marseille
Paris
Augsburg
Halle
Hamburg
Beersheba
Haifa
Petah Tikva
Ramat Gan
Tel Aviv
Soeul
Oviedo
Barcelona
Madrid
Seville
Valencia
Birmingham
Bournemouth
London
Sutton
Lead Sponsor
Incyte Corporation
INDUSTRY